Can a lighter chemo cocktail tame myeloma without the brutal side effects?
NCT ID NCT00734877
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 3 trial tests whether a less intense version of a standard chemotherapy regimen can reduce side effects by half while still controlling low-risk multiple myeloma in adults 65 and under. Participants receive a combination of drugs, a stem cell transplant, and three years of maintenance therapy. The study originally compared two regimens, but the milder arm has been closed, and all new participants now receive the standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- combination chemotherapy (melphalan, bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) followed by stem cell transplant and maintenance therapy
- What this could lead to
- If successful, this could offer a less toxic treatment option for low-risk multiple myeloma that still controls the disease effectively.
- What could go wrong
- This is an early-stage comparison of two intensive regimens; the reduced-toxicity arm has already been closed. The trial is not designed to cure, and long-term side effects from chemotherapy and transplant remain significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW RISK MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy
Little Rock, Arkansas, 72205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact